NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has partnered with Quanterix to create immunoassay services based on Quanterix's Simoa platform.

Myriad RBM, a wholly owned subsidiary of Myriad Genetics, will offer Simoa assay services for the study of inflammatory and autoimmune diseases. Quanterix's Simoa technology uses single molecule measurement to detect protein biomarkers in blood samples. Myriad RBM has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 and tumor necrosis factor alpha, the firm said in a statement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.